Литература

Поставить закладку

1. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sёzary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722
2. Willemze R, Jaffe ES, Burg G, et al: WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785
3. Белоуссова И.Э., Казаков Д.В,, Криволапов Ю.А. Современные подходы к диагностике и лечению первичных лимфом кожи на основе новой ВОЗ-EORTC классификации. Т-клеточные лимфомы кожи. Архив патологии. 2007;69(5):11-17
4. Lutzner M, Edelson R, Schein P, et al: Cutaneous T-cell lymphomas: The Sёzary syndrome, mycosis fungoides, and related disorders. Ann Intern Med. 1975;83:534-552
5. PimpinelliN,OlsenEA,SantucciM,etal.Definingearlymycosisfungoides.JAmAcad Dermatol.2005;53(6):1053-63
6. Братцева Е.В., Ротанов С.В. Современные подходы к диагностике грибовидного микоза.Вестникдерматологииивенерологии.2010;6:16-22
7. KimEJ,HessS,RichardsonSK,etal.ImmunopathogenesisandtherapyofcutaneousT celllymphoma.JClinInvest.2005;115(4):798-812
8. ThurberSE,ZhangB,KimYH,etal.T-cellclonalityanalysisinbiopsyspecimensfrom twodifferentskinsitesshowshighspecificityinthediagnosisofpatientswithsuggested mycosisfungoides.JAmAcadDermatol.2007;57(5):782-90
9. HorwitzSM,OlsenEA,DuvicM,etal.Reviewofthetreatmentofmycosisfungoidesand sёzary syndrome: a stage-based approach. J Natl Compr Canc Netw. 2008;6(4):436-42.
10. Zackheim HS. Treatment of patch-stage mycosis fungoides with topical corticosteroids. DermatolTher.2003;16(4):283-7
11. DiederenPV,vanWeeldenH,SandersCJ,etal.NarrowbandUVBandpsoralen-UVAin the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol.2003;48(2):215-9
12. GathersRC,ScherschunL,MalickF,etal.NarrowbandUVBphototherapyforearly-stage mycosisfungoides.JAmAcadDermatol.2002;47(2):191-7
13. Ponte P, Serrao V, Apetato M. Efficacy of narrowband UVB vs. PUVA in patients with early-stagemycosisfungoides.JEurAcadDermatolVenereol.2010;24(6):716-21
14. QuerfeldC,RosenST,KuzelTM,etal.Long-termfollow-upofpatientswithearly-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.ArchDermatol.2005;141(3):305-11
15. HoppeRT.Mycosisfungoides:radiationtherapy.DermatolTher.2003;16(4):347-54
16. HymesKB.ChoicesinthetreatmentofcutaneousT-celllymphoma.Oncology(Williston Park).2007;21(2Suppl1):18-23
17. KeehnCA,BelongieIP,ShistikG,etal.Thediagnosis,staging,andtreatmentoptionsfor mycosisfungoides.CancerControl.2007;14(2):102-11
18. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther.2006;19(5):264-71
19. Olsen EA. Interferon in the treatment of cutaneous T-cell lymphoma. Dermatol Ther. 2003;16(4):311-21
20. Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides:aretrospectivestudyin69patients.JAmAcadDermatol.2003;49(5):873-8
21. DuvicM,TalpurR,NiX,ZhangC,etal.Phase2trialoforalvorinostat(suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood. 2007;109(1):31-9
22. OlsenEA,KimYH,KuzelTM,etal.PhaseIIbmulticentertrialofvorinostatinpatients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol.2007;25(21):3109-15
23. Duvic M, Olsen EA, Breneman D, et al. Evaluation of the long-term tolerability and clinicalbenefitofvorinostatinpatientswithadvancedcutaneousT-celllymphoma.Clin LymphomaMyeloma.2009;9(6):412-6
24. Wu PA, Kim YH, Lavori PW, et al. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sёzary syndrome. Biol Blood Marrow Transplant. 2009;15(8):982-90
25. Duarte RF, Canals C, Onida F, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sёzary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28(29):4492-9
26. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sёzary syndrome. Blood. 2009;114:4337-53
27. Molin L, Thomsen K, Volden G, et al. Combination chemotherapy in the tumor stage of mycosis fungoides with cyclophosphamide, vincristine, vp-16, adriamycin and prednisolone (COP, CHOP, CAVOP): a report from the Scandinavian mycosis fungoides study group. Acta Derm Venereol. 1980;60(6):542-544
28. Akpek G, Koh HK, Bogen S, O’Hara C, Foss FM. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999;86(7):1368-1376
29. Duvic M, Apisarnthanarax N, Cohen DS, et al. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2003;49(1):35-49
30. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003;98(5):993-1001
31. Tsimberidou AM, Giles F, Duvic M, et al. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer. 2004;100(2):342-349
32. Foss FM, Ihde DC, Linnoila IR, et al. Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome. J Clin Oncol. 1994;12(10):2051-2059
33. Scarisbrick JJ, Child FJ, Clift A, et al. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.Br J Dermatol. 2001;144(5):1010-1015
34. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000;18(13):2603-2606
35. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sёzary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol. 2011; 29: 2598-607
36. Kempf W, Willemze R, Jaffe ES, et al. CD30+ T-cell lymphoproliferative disorders. In: LeBoit P, Burg G, Weedon D, Sarasin A, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Skin Tumours. Lyon, France: IARC Press; 2006;179-181.
37. Ralfkiaer E, Willemze R, Paulli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th ed). Lyon, France: IARC Press; 2008;300-301.
38. Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma
39. Guitart J, Querfeld C. Cutaneous CD30 lymphoproliferative disorders and similar conditions: a clinical and pathologic prospective on a complex issue. Semin Diagn Pathol. 2009;26(3):131-140.
40. Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(2):479-484.
41. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the longterm follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95(12):3653-3661.
42. Liu HL, Hoppe RT, Kohler S, et al. CD30+cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol. 2003; 49(6):1049-1058.
43. Wantzin GL, Thomsen K. PUVA-treatment in lymphomatoid papulosis. Br J Dermatol. 1982; 107(6):687-690.
44. Lange Wantzin G, Thomsen K. Methotrexate in lymphomatoid papulosis. Br J Dermatol. 1984; 111(1):93-95.
45. Fujita H, Nagatani T, Miyazawa M, et al. Primary cutaneous anaplastic large cell lymphoma successfully treated with low-dose oral methotrexate. Eur J Dermatol. 2008;18(3):360-361.

Для продолжения работы требуется Регистрация

Предыдущая страница

Следующая страница